Filter, analyze, and streamline your search for investment opportunities with TipRanks' Stock Screener.

O'Brien covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Dexcom. According to TipRanks, O'Brien has an average return of 0.2% and a 45.38% success rate on recommended stocks.

Currently, the analyst consensus on TransMedics Group is a Moderate Buy with an average price target of $103.13, representing a 48.75% upside. In a report released on February 28, Canaccord Genuity also maintained a Buy rating on the stock with a $104.00 price target.

Based on TransMedics Group's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $121.62 million and a net profit of $6.86 million. In comparison, last year the company earned a revenue of $81.17 million and had a net profit of $4.03 million